Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MDCO message board posts where the ticker symbol MDCO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MDCO SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-015232 Size: 7 KB
2017-12-11
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010400 (34 Act)  Size: 11 KB
2017-12-06 000-31191
171242475
8-K  Documents Current report, items 1.01, 2.05, 8.01, and 9.01
Acc-no: 0001113481-17-000046 (34 Act)  Size: 929 KB
2017-12-04 000-31191
171237904
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014789 Size: 4 KB
2017-12-01
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-027611 Size: 6 KB
2017-11-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014381 Size: 5 KB
2017-11-20
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-17-014380 Size: 6 KB
2017-11-20
8-K  Documents Current report, items 5.02, 5.03, and 9.01
Acc-no: 0001113481-17-000043 (34 Act)  Size: 53 KB
2017-11-15 000-31191
171203934
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014063 Size: 20 KB
2017-11-13
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001113481-17-000040 (34 Act)  Size: 8 MB
2017-11-09 000-31191
171188175
More MDCO SEC Filings


Related news from
Wed, 13 Dec 2017
12:00:00 +0000
The Medicines Company to Host Investor Day on January 23, 2018
The Medicines Company today announced that it will host an Investor Day on Tuesday, January 23, 2018, from 10:00 a.m. to 12:30 p.m., Eastern Time, in New York City.
Tue, 12 Dec 2017
18:36:05 +0000
ETFs with exposure to The Medicines Co. : December 12, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to The Medicines Co. Here are 5 ETFs with the largest exposure to MDCO-US. Comparing the performance and risk of The Medicines Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Fri, 08 Dec 2017
13:06:20 +0000
See what the IHS Markit Score report has to say about Medicines Co.
Medicines Co NASDAQ/NGS:MDCO
Mon, 04 Dec 2017
18:00:00 +0000
[$$] Icahn Protege's Big Biotech Buys: Biogen, Medicines
Sarissa Capital Management last week made nearly $15 million in stock purchases. Sarissa, a hedge fund that specializes in drug developers, added to positions in Biogen (BIIB) and Medicines (MDCO). On Nov. 28 and 29 the fund bought 30,000 shares of Biogen for $9.52 million, or $317.36 each.
Fri, 01 Dec 2017
13:30:00 +0000
Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lannett ...
Fri, 01 Dec 2017
12:30:00 +0000
Blog Exposure - Melinta Therapeutics to Acquire Infectious Disease Business from The Medicines Co.
Stock Monitor: Medicines Co. Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors issued a free report on Melinta Therapeutics, Inc. (NASDAQ: MLNT ) ("Melinta"), ...
Thu, 30 Nov 2017
21:55:09 +0000
Medicines Company to Sell Infectious Disease Unit to Melinta
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Thu, 30 Nov 2017
17:59:13 +0000
Oppenheimer Raises Its Prognosis For The Medicines Company
The Medicines Company (NASDAQ: MDCO ) announced Wednesday an agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT ) for $270 million upfront.  As part of the ...
Thu, 30 Nov 2017
14:25:00 +0000
Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers
The New Haven, Conn.-based firm on Nov. 29 unveiled a deal to acquire The Medicines Co.'s infectious disease unit.
Wed, 29 Nov 2017
21:59:00 +0000
Here's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017
Positive phase 3 data for its lead drug, patisiran, helped shares more than triple this year.
Wed, 29 Nov 2017
21:38:14 +0000
Why Medicines Co. Is Tumbling Despite $270 Million Deal
Shares of Medicines Co. dove to a 21-month low after the biotech sold its infectious diseases unit for $270 million.
Wed, 29 Nov 2017
14:47:12 +0000
The Medicines Company (MDCO): Time For A Financial Health Check
Mid-caps stocks, like The Medicines Company (NASDAQ:MDCO) with a market capitalization of USD $2.21B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap orRead More...
Wed, 29 Nov 2017
12:41:15 +0000
UPDATE: Medicines Co. agrees to sell infectious disease unit to Melinta Therapeutics
The Medicines Co. said Wednesday it has agreed to sell its infectious disease unit to Melinta Therapeutics Inc. for $270 million in upfront consideration, guaranteed payments of $215 million in cash and ...
Wed, 29 Nov 2017
12:12:00 +0000
Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Company
NEW YORK, Nov. 29, 2017 /PRNewswire/ -- Deerfield Management Company announced today it has committed to provide up to $240 million in debt and equity financing to Melinta Therapeutics (MLNT) and up to $100 million in debt financing to The Medicines Company (MDCO) in connection with Melinta's acquisition of the infectious disease business from The Medicines Company. The acquisition includes the purchase of global rights for Vabomere, Orbactiv and Minocin IV and the business unit supporting those products. Upon the closing of the acquisition, Deerfield will provide $190 million in debt and equity funding to Melinta.   Furthermore, Melinta will have the option to draw up to $50 million of debt within 24 months of the closing of the transaction subject to achieving certain sales thresholds.  In addition, Deerfield has agreed to provide up to $100 million in drawable debt financing to The Medicines Company.
Wed, 29 Nov 2017
12:00:00 +0000
The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
The Medicines Company today announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. for $270 million in upfront consideration and guaranteed payments , tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment ...
Wed, 29 Nov 2017
12:00:00 +0000
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
-Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela ®, Vabomere ®, Orbactiv ®, and Minocin IV ®-. -Peak sales potential of the portfolio ...
Fri, 24 Nov 2017
15:45:18 +0000
ETFs with exposure to The Medicines Co. : November 24, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to The Medicines Co. Here are 5 ETFs with the largest exposure to MDCO-US. Comparing the performance and risk of The Medicines Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Tue, 21 Nov 2017
12:00:00 +0000
Earnings Review and Free Research Report: The Medicines Reported Better Than Expected Earnings Results
Research Desk Line-up: Nature's Sunshine Products Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 21, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on The Medicines ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "There is power in numbers. It's obvious that most brokers don't have a clue of what they recommend to clients. Rarely do they own what they are talking about. Here at VF it's real. Real people with real positions giving their takes on the good w/ the bad. "Knowledge always beats strength" is a great quote. Here, at VF, I hope to see the sharing of knowledge become our strength." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards